# Clemens Kratochwil

Source: https://onco.cc/people/clemens-kratochwil/  
OnCo record `clemens-kratochwil` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.

## Summary

Clemens Kratochwil is a nuclear medicine physician at Heidelberg University Hospital, working within the NCT and DKFZ network. His specialisms are targeted alpha therapy, PSMA radioligands and dosimetry in prostate cancer. He reported the first patients treated with actinium-225 PSMA therapy, published in the Journal of Nuclear Medicine as 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. That first clinical experience launched the alpha-emitter era in prostate cancer, and he continues to work on actinium-225 PSMA agents and their dosimetry. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Nuclear medicine physician, Heidelberg University Hospital
- Specialisms: Targeted alpha therapy; PSMA radioligands; Dosimetry

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- drugs: [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/)
- institutions: [European Association of Nuclear Medicine](https://onco.cc/institutions/eanm/), [Heidelberg University Hospital / NCT / DKFZ](https://onco.cc/institutions/heidelberg-nct/)
- journals: [Journal of Nuclear Medicine](https://onco.cc/journals/journal-of-nuclear-medicine/)

---
JSON: https://onco.cc/api/v1/entities/clemens-kratochwil.json